Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience

Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dureja S

Authors: Dureja S, Sen I, Pant V, Thak P,

Keywords: Targeted alpha therapy, TAT, PRRT, neuroendocrine tumors, beta refractory,

#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer

Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Dureja S

Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,

Keywords: PRRT, radiosensitizer,

#1227 Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)

Introduction: Aberrant DNA methylation plays an role in the pathogenesis of many cancers, however little is known about its role in SINET development.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Thirlwell C

Authors: Karpathakis A, Feber A, Morris T, Dibra H, Pipinikas C,

Keywords: Epigenetics, methylation, GIPR, biomarker,

#975 Electron Microscopy of Pancreatic Beta Cell Neuroendocrine Tumors (NETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mice Reveal an Adenomatous Phenotype with Depletion of Insulin Granules and Increased Mitochondrial Content

Introduction: Insulinomas are β cell neuroendocrine tumors (NETs) that secrete insulin, and ~4% of insulinoma patients have multiple endocrine neoplasia type 1 (MEN1). One in ten MEN1 patients present with an insulinoma. Previous reports describe insulinomas as possibly having typical granules (46.4%) or atypical smaller granules (34.3%), both associated with adenomas, or agranular cells (14.3%) associated with carcinomas. MEN1 knockout (Men1+/-) mice develop pancreatic NETs that are mostly insulinomas, and their ultrastructural phenotype is unknown. We hypothesized that these may resemble the adenoma phenotype with atypical granules.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Walls G, Clark A, Thakker R,

Keywords: GEP-NET,

#936 Promoter Hypermethylation at RASSF1 is a Feature of Small Intestinal Neuroendocrine Tumors

Introduction: Promoter hypermethylation of RASSF1 has been reported in many tumor types.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Karpathakis A

Authors: Karpathakis A, Dibra H, Morris T, Feber A, Mandair D,

Keywords: Epigenetics, methylation, RASSF1,